Hans-Peter Gerber
Chief Tech/Sci/R&D Officer chez SUTRO BIOPHARMA, INC.
Profil
Hans-Peter Gerber is currently the Chairman at T-CURX GmbH and the Chief Scientific Officer at Sutro Biopharma, Inc. He previously served as an Independent Director at NBE-Therapeutics AG from 2017 to 2021 and as the President, Director & Chief Science Officer at Maverick Therapeutics, Inc. from 2016 to 2018.
Dr. Gerber holds a doctorate degree from the University of Zurich.
Postes actifs de Hans-Peter Gerber
| Sociétés | Poste | Début |
|---|---|---|
| SUTRO BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 18/09/2023 |
| T-CURX GmbH | Chairman | - |
Anciens postes connus de Hans-Peter Gerber
| Sociétés | Poste | Fin |
|---|---|---|
NBE-Therapeutics AG
 NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Director/Board Member | 01/01/2021 |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | President | 01/01/2018 |
Formation de Hans-Peter Gerber
| University of Zurich | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SUTRO BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Health Technology |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Health Technology |
| T-CURX GmbH |
